About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

NCT01671007·522 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Boehringer Ingelheim

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

1. Age =\>18 years at enrollment
2. Male or female patient (or legally acceptable representative) willing and able to provide written informed consent
3. Patient newly diagnosed (\< 3 months prior to baseline visit) with non-valvular AF and at risk for stroke.

You may not be if

1. Presence of any mechanical heart valve, or valve disease that is expected to require valve replacement intervention;
2. Patients who have received more than 60 days of vitamin K antagonist (VKA) treatment in their lifetime;
3. AF with a generally reversible cause;

The record

StatusCompleted

PhaseNo phase

Taking part10,471

StartedAug 2012

UpdatedDec 31, 2020

Conditions

Stroke Atrial Fibrillation

Where522

Klinik Pirawarth, Therapie und Rehabilitation, Bad Pirawarth
Bad Pirawarth, Austria
KH der Barmherzigen Schwestern Linz
Linz, Austria
Kepler Univ. Klinikum Linz
Linz, Austria

Clareo Health | GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)